Methotrexate vs. Tofacitinib for Moderate-Severe Psoriasis
Treatments studied
Part of Skin clinical trials.
This study compares two systemic medications—methotrexate (a traditional immunosuppressant) and tofacitinib (a newer targeted therapy)—to see which works better for moderate-to-severe plaque psoriasis that hasn't responded well to creams or ointments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have moderate-to-severe plaque psoriasis (the common, scaly type, not other variants like pustular or erythrodermic)
- Your psoriasis has lasted at least 6 months
- Your psoriasis did not improve after at least 4 weeks of topical treatment (creams, ointments, or foams)
- You have not used systemic psoriasis drugs (pills or injections) in the last 4 weeks or topical treatments in the last 2 weeks
- You do not have serious liver, kidney, blood, stomach, or immune-system problems, and are not pregnant, breastfeeding, or planning prolonged sun exposure
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
This study tests whether combining two medicines—methotrexate and tofacitinib—works better for people with a specific type of rheumatoid arthritis. It may be a good fit if you have moderate to severe arthritis, have had a joint biopsy that shows a certain cell pattern, and haven't used similar treatments before.
This trial compares two medications, tofacitinib and methotrexate, to see which works better for severe hair loss caused by alopecia areata. If you have severe alopecia areata (total or universal hair loss), this study may offer a chance to try a new treatment option.
This trial compares two medicines—tofacitinib and methotrexate—to see which works better for controlling active Takayasu’s arteritis. It also looks at safety in people with this condition who need treatment right now.
This pilot study tests whether adding probiotics to standard methotrexate treatment improves symptoms in people newly diagnosed with chronic plaque psoriasis. It aims to see how the gut microbiome affects treatment response.
Hear when a new Chronic Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.